Armata Pharmaceuticals, Inc. — Director's Dealing 2005

Jul 12, 2005

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TARGETED GENETICS CORP /WA/ (TGEN)
CIK: 0000921114
Period of Report: 2002-11-06

Reporting Person: BIOGEN IDEC INC (10% Owner)
Reporting Person: BIOGEN IDEC MA INC (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2002-09-30	Common Stock, $0.01 Par Value	J	104854	$.55	Acquired	9400516	Indirect
2002-11-06	Common Stock, $0.01 Par Value	J	210819	$1.07	Disposed	9611335	Indirect
2003-08-15	Common Stock, $0.01 Par Value	P	2515843	$1.91	Acquired	12127178	Indirect

Footnotes

F1: The reporting person received these shares as additional merger consideration for its preferred shares of Genovo, Inc. exchanged in the merger of a subsidiary of Targeted Genetics Corporation with and into Genovo on September 19, 2000, pursuant to the exercise of the Genzyme Corporation's stock option in connection with the merger.

F2: Shares are owned indirectly by Biogen Idec Inc. and directly by its wholly-owned subsidiary Biogen Idec MA, Inc., fka Biogen, Inc.

F3: The reporting person forfeited these shares on 11/6/2002 to Targeted Genetics in connection with certain of its indemnification claims under the Agreement and Plan of Merger, dated August 8, 2000, among Genovo, Inc., Targeted Genetics, a wholly-owned subsidiary of Targeted Genetics and the reporting person, a stockholder of Genovo.

F4: The reporting person purchased these shares on 8/15/2003 upon exercise by Targeted Genetics of its right to put such shares to the reporting person for purchase under the Funding Agreement dated as of August 8, 2000 between Targeted Genetics and the reporting person.